This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Neurology, Other  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Are Neurologically Active Drugs Important?

Lucette A. J. Cysique, MA; Paul Maruff, PhD; Bruce J. Brew, MBBS, MD, FRACP

Arch Neurol. 2004;61:1699-1704.

Background  The effect on neuropsychological function of antiretroviral drugs that are able to penetrate into the brain in effective concentration (neuroactive drugs) remains unclear.

Objective  To investigate whether highly active antiretroviral therapy (HAART) containing neuroactive drugs is associated with better neuropsychological performance in patients with human immunodeficiency virus disease.

Design  Cross-sectional survey.

Setting  Tertiary referral hospital outpatient clinics.

Patients  The study population consisted of 97 individuals positive for human immunodeficiency virus (stage C3, 1993 Centers for Disease Control and Prevention classification) whose condition had been stable on their current HAART regimen for a mean ± SD of 18.5 ± 16.5 months and who were aged 48.14 ± 9.38 years. The patient groups were analyzed according to whether their regimen contained 3 or more neuroactive drugs (neuroHAART group; n = 41) or not (HAART group; n = 56). Thirty seronegative men matched for age and education were recruited as controls.

Main Outcome Measure  Neuropsychological performance on 7 cognitive domains.

Results  The neuroHAART and HAART groups did not differ from one another on neuropsychological performance, but both patient groups were impaired compared with controls. Impaired patients in each treatment group were compared, and the neuroHAART group showed significantly better memory performance, unrelated to plasma viral load, than the HAART group.

Conclusion  No direct benefit of neuroactive HAART therapy was found in patients with advanced human immunodeficiency virus infection. However, in neuropsychologically impaired patients, there was a benefit in memory function. This suggests that a threshold of neuropsychological impairment is required for the benefit of neuroactive HAART.

Author Affiliations: Faculty of Medicine, St Vincent’s Clinical School, University of New South Wales, Sydney, Australia (Ms Cysique); School of Psychology, LaTrobe University, Melbourne, Australia (Dr Maruff); and Departments of Neurology and HIV Medicine, St Vincent’s Hospital, Sydney (Dr Brew).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy
Cysique et al.
Neurology 2009;73:342-348.
ABSTRACT | FULL TEXT  

Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
Gray et al.
J. Virol. 2009;83:5430-5441.
ABSTRACT | FULL TEXT  

Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region
Wright et al.
Neurology 2008;71:50-56.
ABSTRACT | FULL TEXT  

HIV-associated dementia: An inconvenient truth
Brew and Gonzalez-Scarano
Neurology 2007;68:324-325.
FULL TEXT  

Variable benefit in neuropsychological function in HIV-infected HAART-treated patients
Cysique et al.
Neurology 2006;66:1447-1450.
ABSTRACT | FULL TEXT  

Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline
Thompson et al.
Proc. Natl. Acad. Sci. USA 2005;102:15647-15652.
ABSTRACT | FULL TEXT